- Home
- GOVX vs GELS Comparison
GOVX vs GELS Comparison
Compare GOVX & GELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- GELS
- Stock Information
- Founded
- GOVX 2001
- GELS 2018
- Country
- GOVX United States
- GELS Australia
- Employees
- GOVX N/A
- GELS N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- GELS
- Sector
- GOVX Health Care
- GELS
- Exchange
- GOVX Nasdaq
- GELS NYSE
- Market Cap
- GOVX 15.5M
- GELS 15.9M
- IPO Year
- GOVX N/A
- GELS 2024
- Fundamental
- Price
- GOVX $0.95
- GELS $1.88
- Analyst Decision
- GOVX Strong Buy
- GELS
- Analyst Count
- GOVX 5
- GELS 0
- Target Price
- GOVX $12.40
- GELS N/A
- AVG Volume (30 Days)
- GOVX 1.5M
- GELS 4.0M
- Earning Date
- GOVX 08-05-2025
- GELS 02-15-2025
- Dividend Yield
- GOVX N/A
- GELS N/A
- EPS Growth
- GOVX N/A
- GELS N/A
- EPS
- GOVX N/A
- GELS N/A
- Revenue
- GOVX $5,591,576.00
- GELS $95,618.00
- Revenue This Year
- GOVX N/A
- GELS N/A
- Revenue Next Year
- GOVX N/A
- GELS N/A
- P/E Ratio
- GOVX N/A
- GELS N/A
- Revenue Growth
- GOVX N/A
- GELS N/A
- 52 Week Low
- GOVX $0.73
- GELS $0.77
- 52 Week High
- GOVX $11.18
- GELS $5.50
- Technical
- Relative Strength Index (RSI)
- GOVX 46.22
- GELS N/A
- Support Level
- GOVX $0.85
- GELS N/A
- Resistance Level
- GOVX $1.39
- GELS N/A
- Average True Range (ATR)
- GOVX 0.15
- GELS 0.00
- MACD
- GOVX -0.02
- GELS 0.00
- Stochastic Oscillator
- GOVX 18.52
- GELS 0.00
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.